Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/9672
Title: Antitumor efficacy of cytotoxic drugs and the monoclonal antibody 806 is enhanced by the EGF receptor inhibitor AG1478.
Authors: Johns, Terrance G;Luwor, Rodney B;Murone, Carmel;Walker, Francesca;Weinstock, Janet;Vitali, Angela A;Perera, Rushika M;Jungbluth, Achim A;Stockert, Elisabeth;Old, Lloyd J;Nice, Edouard C;Burgess, Antony W;Scott, Andrew M
Affiliation: Ludwig Institute for Cancer Research, Austin Hospital, Studley Road, Heidelberg 3084, Australia. terry.johns@ludwig.edu.au
Issue Date: 15-Dec-2003
Citation: Proceedings of the National Academy of Sciences of the United States of America 2003; 100(26): 15871-6
Abstract: Blockade of epidermal growth factor receptor (EGFR) signaling with specific inhibitors of the EGFR tyrosine kinase retards cellular proliferation and arrests the growth of tumor xenografts. AG1478, an inhibitor of the EGFR tyrosine kinase, is used in laboratory studies; however, its therapeutic potential has not been elucidated. Therefore, we evaluated an aqueous form of AG1478 for its antitumor activity in mice bearing human xenografts expressing the WT EGFR or a naturally occurring ligand-independent truncation of the EGFR [delta2-7 (de2-7) EGFR or EGFRvIII]. Parenteral administration of soluble AG1478 blocked phosphorylation of the EGFR at the tumor site and inhibited the growth of A431 xenografts that overexpress the WT EGFR and glioma xenografts expressing the de2-7 EGFR. Strikingly, even subtherapeutic doses of AG1478 significantly enhanced the efficacy of cytotoxic drugs, with the combination of AG1478 and temozolomide displaying synergistic antitumor activity against human glioma xenografts. AG1478 was also examined in combination with mAb 806, an anti-EGFR antibody that was raised against the de2-7 EGFR but unexpectedly also binds a subset of the EGFR expressed in cells exhibiting amplification of the EGFR gene. The combination of AG1478 and mAb 806 displayed additive, and in some cases synergistic, antitumor activity against tumor xenografts overexpressing the EGFR. Here, we demonstrate that different classes of inhibitors to the EGFR can have synergistic antitumor activity in vivo. These results establish the antitumor efficacy of the EGFR inhibitor AG1478 and provide a rationale for its clinical evaluation in combination with both chemotherapy and other EGFR therapeutics.
Internal ID Number: 14676326
URI: http://ahro.austin.org.au/austinjspui/handle/1/9672
DOI: 10.1073/pnas.2036503100
URL: http://www.ncbi.nlm.nih.gov/pubmed/14676326
Type: Journal Article
Subjects: Animals
Antineoplastic Agents.toxicity
Carcinoma, Squamous Cell.drug therapy.pathology
Cell Survival.drug effects
Drug Synergism
Enzyme Inhibitors.toxicity
Glioma.drug therapy.pathology
Head and Neck Neoplasms
Humans
Mice
Mice, Nude
Quinazolines
Receptor, Epidermal Growth Factor.antagonists & inhibitors
Transplantation, Heterologous
Tumor Cells, Cultured
Tyrphostins.pharmacokinetics.toxicity
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.